Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Now Sprout Has To Sell Female Sexual Desire Drug Addyi

This article was originally published in The Pink Sheet Daily

Executive Summary

As company gears up for an Oct. 17 launch, with pricing on par with Viagra, commercial challenges include a contraindication and boxed warning against alcohol use.

You may also be interested in...



In Recommending Flibanserin Approval, FDA Panelists Urge Alcohol Contraindication

Panel’s vote to approve Sprout’s female sexual dysfunction drug is conditioned on a REMS and possible contraindication with alcohol use; questions about drug’s date rape potential, breast cancer finding in mice addressed.

Flibanserin Risk Management Challenges: Can A REMS Prevent Alcohol Interactions?

FDA seeks advisory committee views on risk of hypotension and syncope with Sprout’s sexual dysfunction drug flibanserin when used alone or in combination with alcohol, and whether these risks outweigh ‘numerically small’ benefits over placebo.

A New Dawn For Female Sex Dysfunction Drugs? FDA Meeting Cheers Sponsors

Experts convened by FDA to discuss female sexual dysfunction disorders, including problems with desire and arousal, settle on endpoints contrary to new DSM, but are in line with trials of Sprout’s flibanserin, the leading drug in development.

Topics

Related Companies

UsernamePublicRestriction

Register

IV001392

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel